|
Post by lakers on Jan 12, 2017 19:58:34 GMT -5
Progressing pipeline forward with a focus on strategic partnerships [upfront money plus royalty]. As I often said Mnkd wouldn't go alone. Is it clear enough now?
Initial clinical eval criteria Aero performance Ambient temp stability
EpiHale: 2 formulations have been eval'ed Both met performance. PK profiling underway Successful meeting w/ FDA in Dec 2016
PAHale: Tresprostinil, 6 formulations have been eval'ed 4 met performance, moving to PK profiling Additional formulation dev on all 4 continuing in 2Q17
CINV: Palonosetron, 2 formulations have been eval'ed Both showed aceptable aero, will require additional work to improve Ambient temp stability
Eval opps for complementary product [cross-sale, co-market a 36-hr basal as Tresiba by Novo, perhaps?]
|
|